Should I buy or sell Natera stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTRA shares. View NTRA analyst ratings or view top-rated stocks .

What is Natera's stock price target for 2024?

14 Wall Street analysts have issued twelve-month price targets for Natera's stock. Their NTRA share price targets range from $66.00 to $120.00. On average, they anticipate the company's share price to reach $86.40 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price. View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts .

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA shares have increased by 36.1% and is now trading at $85.28. View the best growth stocks for 2024 here .

Are investors shorting Natera?

Natera saw a decrease in short interest in March. As of March 31st, there was short interest totaling 6,250,000 shares, a decrease of 21.4% from the March 15th total of 7,950,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the short-interest ratio is currently 4.1 days. View Natera's Short Interest .

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NTRA earnings forecast .

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings data on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. The medical research company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative trailing twelve-month return on equity of 62.19% and a negative net margin of 40.16%.

What ETFs hold Natera's stock?

ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , Global X Genomics & Biotechnology ETF (GNOM) , Alger Mid Cap 40 ETF (FRTY) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Alger 35 ETF (ATFV) , Principal Healthcare Innovators ETF (BTEC) , VanEck Biotech ETF (BBH) and American Century Mid Cap Growth Impact (MID) .

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com . Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include Xtrackers California Municipal Bond ETF (CA) , BlackRock (BLK) , Endologix (ELGX) , Chipotle Mexican Grill (CMG) , Athabasca Oil (ATH) , NIC (EGOV) , Aegean Marine Petroleum Network (ANW) , Micron Technology (MU) , Transocean (RIG) and Allergan (AGN) .

Natera (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.71%), Sumitomo Mitsui Trust Holdings Inc. (0.31%), Artemis Investment Management LLP (0.19%), Maryland State Retirement & Pension System (0.01%), Banque Cantonale Vaudoise (0.01%) and Wealth Enhancement Advisory Services LLC (0.00%). Insiders that own company stock include Daniel Rabinowitz , Gail Boxer Marcus , Herm Rosenman , James Healy , John Fesko , Jonathan Sheena , Matthew Rabinowitz , Michael Burkes Brophy , Patrick J Donovan, Robert Alan Schueren , Roelof Botha , Rowan E Chapman , Solomon Moshkevich, Steven Leonard Chapman , Todd C Cozzens and Todd C Cozzens . View institutional ownership trends .

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:NTRA

Natera (NTRA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free NTRA Stock Alerts

$85.28

-2.00 (-2.29%)

(As of 04/19/2024 ET)

Compare

Today's Range: $83.13
▼
$87.20
50-Day Range: $68.40
▼
$97.48
52-Week Range: $36.90
▼
$98.82

Volume: 2.53 million shs
Average Volume: 1.48 million shs
Market Capitalization: $10.30 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $86.40

Get Natera alerts:

Natera MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1.3% Upside
$86.40 Price Target
Short Interest: Healthy
5.18% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.92
Based on 15 Articles This Week
Insider Trading: Selling Shares
$36.45 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.35) to ($1.11) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

658th out of 911 stocks

Medical Laboratories Industry

17th out of 20 stocks

2.5

Analyst's Opinion

Consensus Rating
Natera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Natera has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
5.18% of the outstanding shares of Natera have been sold short.
Short Interest Ratio / Days to Cover
Natera has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Natera has recently decreased by 21.38%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Natera does not currently pay a dividend.
Dividend Growth
Natera does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NTRA.

2.7

News and Social Media Coverage

News Sentiment
Natera has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Natera this week, compared to 6 articles on an average week.
Search Interest
Only 9 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.
MarketBeat Follows
Only 11 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,453,056.00 in company stock.
Percentage Held by Insiders
Only 9.42% of the stock of Natera is held by insiders.
Percentage Held by Institutions
99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Natera are expected to grow in the coming year, from ($2.35) to ($1.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Natera is -22.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Natera is -22.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Natera has a P/B Ratio of 13.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NTRA Stock News Headlines

April 19, 2024 | insidertrades.com

Steven Leonard Chapman Sells 6,816 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

April 6, 2024 | insidertrades.com

Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 26,700 Shares of Stock

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 5, 2024 | insidertrades.com

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,378 Shares

March 31, 2024 | insidertrades.com

Jonathan Sheena Sells 447 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

April 19, 2024 | americanbankingnews.com

Solomon Moshkevich Sells 80,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

April 18, 2024 | investing.com

Natera CEO sells shares worth over $630k

April 18, 2024 | finance.yahoo.com

Insider Sell: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 17, 2024 | msn.com

Natera (NTRA) Price Target Increased by 7.38% to 102.96

April 16, 2024 | americanbankingnews.com

Natera (NASDAQ:NTRA) Given New $100.00 Price Target at The Goldman Sachs Group

April 16, 2024 | finance.yahoo.com

Natera, Inc. (NTRA) Interactive Stock Chart - Yahoo Finance

April 12, 2024 | finance.yahoo.com

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

April 11, 2024 | businesswire.com

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

April 10, 2024 | stockhouse.com

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera(TM) Heart dd-cfDNA Test for Heart Transplant Recipients

April 10, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Natera (NTRA) and Mirum Pharmaceuticals (MIRM)

April 8, 2024 | businesswire.com

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

April 5, 2024 | benzinga.com

Cracking The Code: Understanding Analyst Reviews For Natera

April 5, 2024 | msn.com

Natera upgraded at Bernstein on gross margin trajectory

April 5, 2024 | markets.businessinsider.com

Natera Announces Positive Results From IMvigor011 Phase III Study In Muscle-Invasive Bladder Cancer

April 5, 2024 | msn.com

Is Natera (NTRA) On The Cusp Of Being Cash Flow Positive?

April 5, 2024 | businesswire.com

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

April 5, 2024 | finance.yahoo.com

Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)

April 1, 2024 | finance.yahoo.com

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

March 31, 2024 | investing.com

Natera CFO exercises options and sells shares worth over $82,000

March 22, 2024 | seekingalpha.com

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

March 20, 2024 | finance.yahoo.com

Will Natera (NTRA) Continue to Deliver Solid Topline Growth?

See More Headlines

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:NTRA
CUSIP: N/A
CIK: 1604821
Web: www.natera.com
Phone: (650) 249-9090
Fax: N/A
Employees: 3,293
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $86.40
High Stock Price Target: $120.00
Low Stock Price Target: $66.00
Potential Upside/Downside: +1.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-434,800,000.00
Net Margins: -40.16%
Pretax Margin: -40.14%
Return on Equity: -62.19%
Return on Assets: -31.88%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 4.10
Quick Ratio: 3.96

Sales & Book Value

Annual Sales: $1.08 billion
Price / Sales: 9.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.37 per share
Price / Book: 13.39

Miscellaneous

Outstanding Shares: 120,758,000
Free Float: 109,383,000
Market Cap: $10.30 billion
Optionable: Optionable
Beta: 1.37

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Matthew Rabinowitz Ph.D. (Age 51)
Co-Founder & Executive Chairman
Comp: $441.58k
Mr. Steven Leonard Chapman (Age 45)
CEO & Director
Comp: $1.15M
Mr. Michael B. Brophy M.B.A. (Age 44)
Chief Financial Officer
Comp: $611.35k
Mr. Daniel Rabinowitz L.L.M. (Age 55)
Secretary & Chief Legal Officer
Comp: $566.03k
Mr. John Fesko
President & Chief Business Officer
Mr. Jonathan Sheena M.Eng. (Age 51)
Co-Founder & Director
Comp: $293.91k
Ms. Olesya A. Anisimova CPA
Chief Accounting Officer
Mr. Rishi Kacker
Chief Technology Officer
Mr. Eric A. Evans
Chief Scientific Officer
Mr. Jerry Diffley
Chief Compliance & Privacy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.
What is Natera's stock price target for 2024?: 14 Wall Street analysts have issued twelve-month price targets for Natera's stock. Their NTRA share price targets range from $66.00 to $120.00. On average, they anticipate the company's share price to reach $86.40 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.
How have NTRA shares performed in 2024?: Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA shares have increased by 36.1% and is now trading at $85.28.
View the best growth stocks for 2024 here.
Are investors shorting Natera?: Natera saw a decrease in short interest in March. As of March 31st, there was short interest totaling 6,250,000 shares, a decrease of 21.4% from the March 15th total of 7,950,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the short-interest ratio is currently 4.1 days.
View Natera's Short Interest.
When is Natera's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NTRA earnings forecast.
How were Natera's earnings last quarter?: Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings data on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. The medical research company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative trailing twelve-month return on equity of 62.19% and a negative net margin of 40.16%.
What ETFs hold Natera's stock?: ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Genomics & Biotechnology ETF (GNOM), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alger 35 ETF (ATFV), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH) and American Century Mid Cap Growth Impact (MID).

What guidance has Natera issued on next quarter's earnings?: Natera issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.
What is Steve Chapman's approval rating as Natera's CEO?: 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Natera own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).
When did Natera IPO?: Natera (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Who are Natera's major shareholders?: Natera's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.71%), Sumitomo Mitsui Trust Holdings Inc. (0.31%), Artemis Investment Management LLP (0.19%), Maryland State Retirement & Pension System (0.01%), Banque Cantonale Vaudoise (0.01%) and Wealth Enhancement Advisory Services LLC (0.00%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Solomon Moshkevich, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends.
How do I buy shares of Natera?: Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial